可溶性CD163预测接受化学免疫治疗和靶向治疗的套细胞淋巴瘤患者的结局
研究纳入131例套细胞淋巴瘤(MCL)患者,评估血清可溶性CD163(sCD163)的预后价值。在81例初诊接受化学免疫治疗的患者和50例复发后主要接受利妥昔单抗、伊布替尼和来那度胺治疗的患者中,诊断时高sCD163均与更短的无进展生存期(PFS)和总生存期(OS)相关。初诊且sCD163低水平患者5年生存率为97%。sCD163与组织CD163中度相关,其不良预后关联独立于MCL国际预后指数、Ki67、p53状态和母细胞样形态。
要点
- 诊断时高sCD163与初诊化学免疫治疗和复发靶向治疗MCL患者更短PFS和OS相关。
- 初诊且sCD163低水平患者5年生存率达97%。
- sCD163与组织CD163中度相关,其预后关联独立于MIPI、Ki67、p53状态和母细胞样形态。
核心结论
- 高sCD163与更短PFS和更短OS相关,表明高水平的M2巨噬细胞标志物sCD163是MCL在化学免疫治疗和伊布替尼/来那度胺时代的独立不良预后因素。
- 低sCD163水平可识别预后非常好的MCL患者。
研究设计与样本
- 研究纳入131例MCL患者,其中81例为初诊后接受化学免疫治疗,50例为复发MCL且主要在接受利妥昔单抗、伊布替尼和来那度胺治疗的2期Philemon试验中治疗。
主要发现
- 在81例初诊接受化学免疫治疗的患者中,诊断时高sCD163与更短PFS和更短OS相关。
- 在50例复发MCL患者中(主要接受利妥昔单抗、伊布替尼和来那度胺治疗),高sCD163同样与更短PFS和更短OS相关。
- 初诊且sCD163低水平患者5年生存率为97%。
- sCD163与组织CD163呈中度相关。
- 多变量Cox比例风险模型显示,sCD163与不良预后的关联独立于MCL国际预后指数、Ki67、p53状态和母细胞样形态。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The outcome for patients with mantle cell lymphoma (MCL) has drastically improved with new treatments directed toward the tumor immune microenvironment, where macrophages play an important role. In MCL, the presence of M2 macrophages defined by CD163 expression in diagnostic biopsies has been associated with a worse prognosis. An alternative way to assess the abundance of M2 macrophages is by measuring the level of soluble CD163 in serum (sCD163). We aimed to investigate the prognostic value of sCD163 in 131 patients with MCL. We found that high sCD163 at diagnosis was associated with shorter progression-free survival (PFS) and shorter overall survival (OS) in 81 patients who were newly diagnosed and subsequently treated with chemoimmunotherapy. The same was seen in a cohort of 50 patients with relapsed MCL that were mainly treated within the phase 2 Philemon-trial with rituximab, ibrutinib, and lenalidomide. In patients who were newly diagnosed and had low levels of sCD163, 5-year survival was 97%. There was a moderate correlation between sCD163 and tissue CD163. The association with a poor prognosis was independent of MCL international prognostic index, Ki67, p53 status, and blastoid morphology, as assessed in a multivariable Cox proportional hazards model. In this study, high sCD163 was associated with both shorter PFS and shorter OS, showing that high levels of the M2 macrophage marker sCD163 is an independent negative prognostic factor in MCL, both in the chemoimmunotherapy and ibrutinib/lenalidomide era. In addition, low sCD163 levels identify patients with MCL with a very good prognosis.
引用
- Nikkarinen A, Lokhande L, Amini RM, et al. Soluble CD163 predicts outcome in both chemoimmunotherapy and targeted therapy-treated mantle cell lymphoma. Blood Adv. 2023. PMID: 37389827. doi:10.1182/bloodadvances.2023010052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。